Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
Assay dependent |
Assay dependent |
Assay dependent |
Assay dependent |
Not tested in other applications.
Calculated MW
Product Note
Reacts with reduced and non-reduced MMP-19. Recognizes the pro-form and most active forms of MMP-19. The hemopexin domain is cleaved from the smallest active form of MMP-19 and the antibody does not detect this form.
Form
Liquid
Buffer
PBS, 50% Glycerol
Preservative
0.1% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
Concentration
~1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Synthetic peptide (Human) (C terminal).
Purification
Purified by affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
matrix metallopeptidase 19 , CODA , MMP18 , RASI-1
Background
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development,reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases.
Database
Research Area